Background: Hypocalacemia is the most common major adverse event in patients with osteoporosis receiving the bone resorption inhibitor denosumab and has been reported in patients with metastatic bone disease and stage 4 and 5 chronic kidney disease. Little is known in patients without these co-morbidities. Untreated hypocalcaemia may lead to prolonged QT, congestive cardiac failure, hypotension and seizures. Methods: A prospective cohort study was undertaken between May 2015 and May 2017 of inpatients aged >65 years with a new diagnosis of osteoporosis. Patients were initiated on denosumab therapy and monitored to identify who developed hypocalcaemia (<2.10 mmol/l) by day 10 post first dose. Patients were recruited from an Irish acute tertiary hospital and 2 affiliated rehabilitation units in the same county. Patients with eGFR < 30 ml/min/1.73 m2 or receiving dialysis were excluded from the study, as were patients with metastatic bone disease. Baseline biochemical serological tests, including calcium, vitamin D and PTH were collected prior to initial dosing of Denosumab along with documentation of past medical history, current medications, vitamin supplements and a resting ECG.Indicators of frailty including weight, Timed Get Up and Go (TUG) and Modified Barthel Index were recorded.
Patients were re-evaluated 10 days post-Denosumab dose for hypocalacaemia with repeat serological testing. Results: Sixty patients were recruited in the study. 82% were women. Median age 80.4 years. Baseline biochemical tests were normal in all participants. Four patients (6%) developed hypocalcemia by day 10 post Denosumab therapy initiation (range 1.83 mmol/l-2.10 mmol/l). All were asymptomatic with no ECG changes. None required hospitalisation but were treated with calcium supplementation. Median TUG score 20.9 seconds. Median Modified Barthel Index 15.7 Conclusions: Our study demonstrated the importance of monitoring calcium levels and renal function before and during denosumab therapy in patients with multiple comorbidities. Vigilance is required amongst physicians and GPs who initiate denosumab therapy.
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